Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody

Retrovirology

Volumn 7, Issue , 2010, Pages

  Willett, Brian J ^a   Kraase, Martin ^a   Logan, Nicola ^a   McMonagle, Elizabeth L ^a   Samman, Ayman ^a   Hosie, Margaret J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS ANTIBODY; VIRUS RECEPTOR;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FELINE IMMUNODEFICIENCY VIRUS; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IN VIVO STUDY; LENTIVIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; VIRUS CELL INTERACTION; ANIMAL; CAT; CHEMICAL STRUCTURE; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; GENETIC SELECTION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; PROTEIN CONFORMATION; VIROLOGY; VIRUS ATTACHMENT;

FELINE IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; MODELS, MOLECULAR; MUTATION, MISSENSE; PROTEIN CONFORMATION; RECEPTORS, VIRUS; SELECTION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRUS ATTACHMENT;

EID: 77951215784     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-38     Document Type: Article

References (67)

1. Torten M, Franchini M, Barlough JE, George JW, Mozes E, Lutz H, Pedersen NC. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol 1991, 65:2225-2230. 240570, 1673159.
2. Ackley CD, Yamamoto JK, Levy N, Pedersen NC, Cooper MD. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 1990, 64:5652-5655. 248623, 1976826.
3. Yamamoto JK, Hansen H, Ho EW, Morishita TY, Okuda T, Saura TR, Nakamura RM, Pedersen NC. Epidemiologic and clinical aspects of FIV infection in cats from the continental U.S. and Canada and possible mode of transmission. J Am Vet Med Assoc 1989, 194:213-220.
4. Sparger EE, Luciw PA, Elder JH, Yamamoto JK, Lowenstine LJ, Pedersen NC. Feline immunodeficiency virus is a lentivirus associated with an AIDS-like disease in cats. AIDS 1989, 3:S43-S49. 10.1097/00002030-198901001-00006, 2558688.
5. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency syndrome. Science 1987, 235:790-793. 10.1126/science.3643650, 3643650.
6. Hosie MJ, Robertson C, Jarrett O. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom. Vet Rec 1989, 125:293-297.
7. Pedersen NC. The feline immunodeficiency virus. The Retroviridae 1993, 181-228. New York: Plenum Press, Levy JA.
8. Callanan JJ, Thompson H, Toth SR, O'Neil B, Lawrence CE, Willett BJ, Jarrett O. Clinical and pathological findings in feline immunodeficiency virus experimental infection. Vet Immunol Immunopathol 1992, 35:3-13. 10.1016/0165-2427(92)90116-8, 1337400.
9. Callanan JJ, Jones BA, Irvine J, Willett BJ, McCandlish IAP, Jarrett O. Histological classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections. Vet Pathol 1996, 33:264-272. 10.1177/030098589603300302, 8740699.
10. Murray JK, Browne WJ, Roberts MA, Whitmarsh A, Gruffydd-Jones TJ. Number and ownership profiles of cats and dogs in the UK. Vet Rec 2010, 166:163-168.
11. Willett BJ, Flynn JN, Hosie MJ. FIV infection of the domestic cat: an animal model for AIDS. Immunol Today 1997, 18:182-189. 10.1016/S0167-5699(97)84665-8, 9136455.
12. Bendinelli M, Pistello M, Lombardi S, Poli A, Garzelli C, Matteucci D, Ceccherini-Nelli L, Malvaldi G, Tozzini F. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995, 8:87-112. 172850, 7704896.
13. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348. 10.1016/0092-8674(86)90590-8, 3094962.
14. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767. 10.1038/312763a0, 6096719.
15. Klatzmann D, Champagne E, Chamaret S, Guetard D, Hercend T, Gluckmann JC, Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768. 10.1038/312767a0, 6083454.
16. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877. 10.1126/science.272.5263.872, 8629022.
17. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: A RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958. 10.1126/science.272.5270.1955, 8658171.
18. Dragic T, Litwin T, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR5. Nature 1996, 381:667-673. 10.1038/381667a0, 8649512.
19. Deng H, Liu R, Ellmeir W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666. 10.1038/381661a0, 8649511.
20. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors:Roles in viral entry, tropism, and disease. Annual Review of Immunology 1999, 17:657-700. 10.1146/annurev.immunol.17.1.657, 10358771.
21. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997, 185:621-628. 10.1084/jem.185.4.621, 2196142, 9034141.
22. Bjorndal A, Deng HK, Jansson M, Fiore JR, Colognesis C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997, 71:7478-7487. 192094, 9311827.
23. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10489-10502. 113104, 10559367.
24. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265. 10.1038/nm1197-1259, 9359702.
25. Tasca S, Ho SH, Cheng-Mayer C. R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. J Virol 2008, 82:7089-7099. 10.1128/JVI.00570-08, 2446975, 18480460.
26. Philpott SM. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003, 1:217-227. 10.2174/1570162033485357, 15043204.
27. Willett BJ, McMonagle EL, Ridha S, Hosie MJ. Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus (FIV). J Virol 2006, 80:3386-3394. 10.1128/JVI.80.7.3386-3394.2006, 1440405, 16537606.
28. Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H, Akashi H, Takeuchi Y, Hosie MJ, Willett BJ. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004, 303:1192-1195. 10.1126/science.1092124, 14976315.
29. de Parseval A, Chatterji U, Sun P, Elder JH. Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci USA 2004, 101:13044-13049. 10.1073/pnas.0404006101, 516514, 15326292.
30. Willett BJ, Hosie MJ, Neil JC, Turner JD, Hoxie JA. Common mechanism of infection by lentiviruses. Nature 1997, 385:587. 10.1038/385587a0, 9024654.
31. Willett BJ, Picard L, Hosie MJ, Turner JD, Adema K, Clapham PR. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 1997, 71:6407-6415. 191914, 9261358.
32. Poeschla EM, Looney DJ. CXCR4 requirement for a nonprimate lentivirus:heterologous expression of FIV in human, rodent and feline cells. J Virol 1998, 72:6858-6866. 109895, 9658135.
33. Richardson J, Pancino G, Leste-Lasserre T, Schneider-Mergener J, Alizon M, Sonigo P, Heveker N. Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus. J Virol 1999, 73:3661-3671. 104141, 10196258.
34. Egberink HF, De Clercq E, Henson G, Balzarini J, Horzinek MC, Schols D. The bicyclam AMD3100, a selective antagonist of the human chemokine receptor CXCR4, inhibits feline immunodeficiency virus (FIV) replication in vitro. Fourth International Feline Retrovirus Research Symposium 1998, A3.3:26.
35. Willett BJ, Cannon CA, Hosie MJ. Upregulation of surface feline CXCR4 expression following ectopic expression of CCR5: implications for studies of the cell tropism of feline immunodeficiency virus. J Virol 2002, 76:9242-9252. 10.1128/JVI.76.18.9242-9252.2002, 136470, 12186908.
36. Willett BJ, Hosie MJ. Chemokine receptors and co-stimulatory molecules: Unravelling feline immunodeficiency virus infection. Vet Immunol Immunopathol 2008, 123:56-64. 10.1016/j.vetimm.2008.01.012, 2413005, 18289703.
37. Willett BJ, McMonagle EL, Bonci F, Pistello M, Hosie MJ. Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus. J Virol 2006, 80:7744-7747. 10.1128/JVI.00722-06, 1563730, 16840353.
38. Willett BJ, McMonagle EL, logan N, Schneider P, Hosie MJ. Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Mol Immunol 2009, 46:1020-30. 10.1016/j.molimm.2008.08.271, 2676423, 19181384.
39. Willett BJ, McMonagle EL, logan N, Spiller OB, Schneider P, Hosie MJ. Probing the interaction between the feline immunodeficiency virus and CD134 using a novel monoclonal antibody 7D6 and CD134L (OX40L). J Virol 2007, 81:9665-9679. 10.1128/JVI.01020-07, 2045395, 17609274.
40. Willett BJ, Hosie MJ. The Felid Immunodeficiency Viruses: Viral Cell Tropism and the Pathogenesis of Feline AIDS. Lentiviruses and Macrophages 2010, 231-250. Norfolk: Caister Academic Press, Moira Desport.
41. Hosie MJ, Willett BJ, Klein D, Dunsford TH, Cannon C, Shimojima M, Neil JC, Jarrett O. Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J Virol 2002, 76:6062-6072. 10.1128/JVI.76.12.6062-6072.2002, 136200, 12021339.
42. Kraase M, Sloan R, Klein D, logan N, McMonagle L, Biek R, Willett BJ, Hosie MJ. Feline immunodeficiency virus env gene evolution in experimentally infected cats. Vet Immunol Immunopathol 2010, 134:96-106. 10.1016/j.vetimm.2009.10.015, 19897254.
43. Dubridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987, 7:379-387. 365079, 3031469.
44. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90:8392-8396. 10.1073/pnas.90.18.8392, 47362, 7690960.
45. Miyazawa TM, Furuya T, Itagaki S, Tohya Y, Takahashi E, Mikami T. Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus. Arch Virol 1989, 108:131-135. 10.1007/BF01313750, 2480760.
46. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944. 10.1006/viro.1995.1016, 7531918.
47. Hosie MJ, Dunsford T, Klein D, Willett BJ, Cannon C, Osborne R, Macdonald J, Spibey N, Mackay N, Jarrett O, Neil JC. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol 2000, 74:9403-9411. 10.1128/JVI.74.20.9403-9411.2000, 112369, 11000209.
48. Cheney CM, Rojko JL, Kociba GJ, Wellman ML, Di Bartola SP, Rezanka LJ, Forman L, Mathes LE. A feline large granular lymphoma and its derived cell line. In Vitro Cell Dev Biol 1990, 26:455-463. 10.1007/BF02624087, 2161827.
49. Willett BJ, McMonagle EL, logan N, Samman A, Hosie MJ. A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction. Retrovirology 2008, 5:77. 10.1186/1742-4690-5-77, 2563026, 18721458.
50. de Parseval A, Grant CK, Sastry KJ, Elder JH. Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope. J Virol 2006, 80:3088-3091. 10.1128/JVI.80.6.3088-3091.2006, 1395450, 16501119.
51. de Parseval A, Chatterji U, Morris G, Sun P, Olson AJ, Elder JH. Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus. Nat Struct Mol Biol 2004, 12:60-66. 10.1038/nsmb872, 15592478.
52. McKnight A, Clapham PR. Immune escape and tropism of HIV. Trends Microbiol 1995, 3:356-361. 10.1016/S0966-842X(00)88975-1, 8520889.
53. McKnight A, Weiss RA, Shotton C, Takeuchi Y, Hoshino H, Clapham PR. Change in tropism upon immune escape by human immunodeficiency virus. J Virol 1995, 69:3167-3170. 189019, 7707545.
54. Quakkelaar ED, Beaumont T, van Nuenen AC, van Alphen FP, Boeser-Nunnink BD, 't Wout AB, Schuitemaker H. T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates. Virology 2007, 359:92-104. 10.1016/j.virol.2006.09.021, 17052738.
55. English RV, Johnson CM, Gebhard DH, Tompkins MB. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 1993, 67:5175-5186. 237915, 7688819.
56. Dean GA, Reubel GH, Moore PF, Pedersen NC. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol 1996, 70:5165-5169. 190471, 8764024.
57. Kimata JT, Gosink JJ, KewalRamani VN, Rudensey LM, Littman DR, Overbaugh J. Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J Virol 1999, 73:1655-1660. 103994, 9882375.
58. Kitchen CM, Philpott S, Burger H, Weiser B, Anastos K, Suchard MA. Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral Therapy: a Bayesian approach. J Virol 2004, 78:11296-11302. 10.1128/JVI.78.20.11296-11302.2004, 521818, 15452249.
59. Stalmeijer EH, Van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D, Schuitemaker H. In vivo evolution of ×4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol 2004, 78:2722-2728. 10.1128/JVI.78.6.2722-2728.2004, 353738, 14990692.
60. Hu QX, Barry AP, Wang ZX, Connolly SM, Peiper SC, Greenberg ML. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol 2000, 74:11858-11872. 10.1128/JVI.74.24.11858-11872.2000, 112469, 11090186.
61. Lauren A, Vodros D, Thorstensson R, Fenyo EM. Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): evolution of coreceptor use varies with pathogenic outcome. JGV 2006, 87:581-594.
62. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004, 78:524-530. 10.1128/JVI.78.1.524-530.2004, 303404, 14671134.
63. Siebelink KHJ, Huisman W, Karlas JA, Rimmelzwaan GF, Bosch ML, Osterhaus ADME. Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein. J Virol 1996, 69:5124-5127.
64. Bendinelli M, Pistello M, Del Mauro D, Cammarota G, Maggi F, Leonildi A, Giannecchini S, Bergamini C, Matteucci D. During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. J Virol 2001, 75:4584-4593. 10.1128/JVI.75.10.4584-4593.2001, 114211, 11312328.
65. Giannecchini S, Matteucci D, Ferrari A, Pistello M, Bendinelli M. Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro. J Virol 2001, 75:8868-8873. 10.1128/JVI.75.18.8868-8873.2001, 115134, 11507234.
66. Samman A, logan N, McMonagle EL, Ishida T, Mochizuki M, Willett BJ, Hosie MJ. Neutralisation of feline immunodeficiency virus by antibodies targeting the V5 Loop of Env. J Gen Virol 2010, 91:242-9. 10.1099/vir.0.015404-0, 19776242.
67. Pancino G, Fossati I, Chappey C, Castelot S, Hurtrel B, Moraillon A, Klatzmann D, Sonigo P. Structure and variations of feline immunodeficiency virus envelope glycoproteins. Virology 1993, 192:659-662. 10.1006/viro.1993.1083, 8380668.